Suppr超能文献

胰岛素泵治疗1型糖尿病患儿的长期疗效

Long-term efficacy of insulin pump therapy in children with type 1 diabetes mellitus.

作者信息

Batajoo Ruby Joshi, Messina Catherine R, Wilson Thomas A

机构信息

Stony Brook University, Department of Pediatrics, Stony Brook, NY, USA.

出版信息

J Clin Res Pediatr Endocrinol. 2012 Sep;4(3):127-31. doi: 10.4274/Jcrpe.751.

Abstract

OBJECTIVE

Insulin pumps have been well established for insulin delivery. However, questions about long-term efficacy of insulin pump therapy still remain. We evaluated the long-term efficacy of continuous insulin infusion pump therapy (CSII) in pediatric patients with type 1 diabetes mellitus (T1DM).

METHODS

This was a retrospective observational study which included 131 patients with T1DM who transitioned to an insulin pump from multiple daily insulin (MDI) injections between 1999 and 2009 and were followed by one endocrinologist. Data were collected from 6 months prior to switching to CSII to 30 months after initiation of CSII and included glycated hemoglobin (HbA1c) and insulin requirement. Of the 131 patients, 45 had complete data consisting of a visit and HbA1c every 6 months for 30 months after transition to CSII and were included for analysis.

RESULTS

Mean HbA1c prior to starting the CSII was 8.0 +0.9 %, 7.7 +1.0 % at 6 months and 7.8+1.2 % at 1 yr post initiation of CSII. However, at 30 months, HbA1c increased to 8.0+1.3%. A trend in transient improvement in HbA1c was limited only to those patients >11 yr of age and those requiring >0.75 u/kg/day of insulin at transition and was not seen in those <11 yr of age or those requiring <0.75 u/kg/day and did not persist beyond 1 year.

CONCLUSIONS

There was no long-term significant difference in glycemic control in patients with CSII as compared to MDI.

摘要

目的

胰岛素泵已被广泛应用于胰岛素输注。然而,胰岛素泵治疗的长期疗效仍存在疑问。我们评估了持续皮下胰岛素输注泵治疗(CSII)对1型糖尿病(T1DM)儿童患者的长期疗效。

方法

这是一项回顾性观察研究,纳入了131例T1DM患者,他们于1999年至2009年间从多次皮下注射胰岛素(MDI)转换为胰岛素泵治疗,并由一名内分泌科医生进行随访。收集的数据从转换为CSII前6个月至CSII开始后30个月,包括糖化血红蛋白(HbA1c)和胰岛素需求量。131例患者中,45例有完整数据,包括转换为CSII后30个月内每6个月的一次就诊和HbA1c检测结果,并纳入分析。

结果

开始CSII治疗前的平均HbA1c为8.0 +0.9%,CSII开始后6个月时为7.7 +1.0%,1年后为7.8+1.2%。然而,在30个月时,HbA1c升至8.0+1.3%。HbA1c短暂改善的趋势仅局限于那些年龄>11岁且转换时胰岛素需求量>0.75 u/kg/天的患者,而年龄<11岁或胰岛素需求量<0.75 u/kg/天的患者未出现该趋势,且这种改善在1年后未持续。

结论

与MDI相比,CSII治疗患者的血糖控制在长期并无显著差异。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3278/3459160/bef5da217bfc/JCRPE-4-127-g2.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验